- Mylan’s stock dropped 7.4% shortly after markets opened on Wednesday due to poor second quarter earnings.
- The company’s total revenue for the second quarter was $2.8 billion, down 5% compared to last year. Sales in North America also fell 22%.
- Mylan then announced that it was going to conduct a strategic review of the company, saying it believes it is undervalued. This means the company could be broken up or sold.
- Mylan N.V. is an American pharmaceutical company registered in the Netherlands that makes both generic and specialty drugs. It is best known as the manufacturer of EpiPen.
Source: Business insider